Cargando…
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated wi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/ https://www.ncbi.nlm.nih.gov/pubmed/24450548 http://dx.doi.org/10.1186/1471-244X-14-16 |
_version_ | 1782301366823157760 |
---|---|
author | Lachaine, Jean Beauchemin, Catherine Mathurin, Karine Gilbert, Dominique Beillat, Maud |
author_facet | Lachaine, Jean Beauchemin, Catherine Mathurin, Karine Gilbert, Dominique Beillat, Maud |
author_sort | Lachaine, Jean |
collection | PubMed |
description | BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated with a favourable metabolic profile and minimal weight gain potential. This study aimed to assess the economic impact of asenapine compared to olanzapine in the treatment of BPD in Canada. METHODS: A decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine compared with olanzapine. The decision tree takes into account the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases (CHDs), and stroke. Analyses were conducted from both a Canadian Ministry of Health (MoH) and a societal perspective over a five-year time horizon with yearly cycles. RESULTS: In the treatment of BPD, asenapine is a dominant strategy over olanzapine from both a MoH and a societal perspective. In fact, asenapine is associated with lower costs and more quality-adjusted life years (QALYs). Results of the probabilistic sensitivity analysis indicated that asenapine remains a dominant strategy in 99.2% of the simulations, in both a MoH and a societal perspective, and this result is robust to the many deterministic sensitivity analyses performed. CONCLUSIONS: This economic evaluation demonstrates that asenapine is a cost-effective strategy compared to olanzapine in the treatment of BPD in Canada. |
format | Online Article Text |
id | pubmed-3905654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39056542014-01-30 Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada Lachaine, Jean Beauchemin, Catherine Mathurin, Karine Gilbert, Dominique Beillat, Maud BMC Psychiatry Research Article BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated with a favourable metabolic profile and minimal weight gain potential. This study aimed to assess the economic impact of asenapine compared to olanzapine in the treatment of BPD in Canada. METHODS: A decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine compared with olanzapine. The decision tree takes into account the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases (CHDs), and stroke. Analyses were conducted from both a Canadian Ministry of Health (MoH) and a societal perspective over a five-year time horizon with yearly cycles. RESULTS: In the treatment of BPD, asenapine is a dominant strategy over olanzapine from both a MoH and a societal perspective. In fact, asenapine is associated with lower costs and more quality-adjusted life years (QALYs). Results of the probabilistic sensitivity analysis indicated that asenapine remains a dominant strategy in 99.2% of the simulations, in both a MoH and a societal perspective, and this result is robust to the many deterministic sensitivity analyses performed. CONCLUSIONS: This economic evaluation demonstrates that asenapine is a cost-effective strategy compared to olanzapine in the treatment of BPD in Canada. BioMed Central 2014-01-22 /pmc/articles/PMC3905654/ /pubmed/24450548 http://dx.doi.org/10.1186/1471-244X-14-16 Text en Copyright © 2014 Lachaine et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lachaine, Jean Beauchemin, Catherine Mathurin, Karine Gilbert, Dominique Beillat, Maud Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada |
title | Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada |
title_full | Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada |
title_fullStr | Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada |
title_full_unstemmed | Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada |
title_short | Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada |
title_sort | cost-effectiveness of asenapine in the treatment of bipolar disorder in canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/ https://www.ncbi.nlm.nih.gov/pubmed/24450548 http://dx.doi.org/10.1186/1471-244X-14-16 |
work_keys_str_mv | AT lachainejean costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada AT beauchemincatherine costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada AT mathurinkarine costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada AT gilbertdominique costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada AT beillatmaud costeffectivenessofasenapineinthetreatmentofbipolardisorderincanada |